Joseph I Walton DeceasedTucson, AZ

2021012, Apr 22, 2021

Apr 13, 2018

16/604728

David Eddins - Odessa FL, US
Joseph Walton - Tampa FL, US

H04R 25/00

A device and method that supplements sensory input, thereby providing a supplemented sensory environment, to induce plasticity within the central nervous system that effectively overcomes sensory-neural processing deficits or strengthens specific sensory-neural abilities. In one implementation, ear-level hearing devices are used to deliver therapeutic sound with specific acoustic features that serve as archetypes of stimulus features for which sensory-neural processing is compromised by a sensory-neural deficit.

2019021, Jul 18, 2019

Mar 6, 2018

15/912692

- Tampa FL, US
Robert Dana Frisina - Tampa FL, US
Joseph Paul Walton - Tampa FL, US
Venkat Rama Bhethanabotla - Tampa FL, US

A61N 5/06
A61N 5/067

A novel method to stimulate electrically active biological cells using visible wavelength light and metallic nanoparticles possessing plasmonic properties is presented herein. Using this technology, prosthetic devices such as cochlear and retinal implants and cardiac pacemakers can be developed to have superior properties as compared to the currently utilized electrical stimulation designs. These properties include improved spatial resolution; less or non-invasive devices; and higher fidelity of transduction. An additional advantage of using visible light wavelengths is the avoidance of unwanted heating of surrounding tissue that occurs with infrared stimulation.

2016037, Dec 29, 2016

Jun 29, 2016

15/196878

Robert Dana Frisina - Tampa FL, US
Joseph Paul Walton - Tampa FL, US
Bo Ding - Tampa FL, US
Xiaoxia Zhu - Tampa FL, US

University of South Florida - Tampa FL

A61K 31/573
A61K 33/02
A61K 31/192
A61K 45/06
A61K 31/616

Permanent hearing loss or deafness affects about 15% of people worldwide, about 40 million in the US alone. There are currently no FDA-approved drugs on the market in the US, or anywhere in the world that prevent, treat or reverse permanent hearing loss or deafness. Age-related hearing loss (ARHL) is one of the most common forms of permanent hearing loss and deafness. ARHL is the #1 neurodegenerative disorder, #1 communication disorder, and 1 of the top 3 chronic medical conditions (along with arthritis & cardiovascular diseases) of our aged population. The incidence of ARHL is increasing due to the “Baby Boomers” reaching old age, and cumulative effects of lifetime noise exposure, and widespread use of chemotherapeutic and antibiotic drugs, which are ototoxic, or have ototoxic side effects. A new drug is disclosed to prevent or slow the progression of ARHL, based upon natural, existing FDA-approved compounds that are on the market to treat other non-ARHL biomedical problems. When given in the proper dosage the compounds have few, if any side effects, and initial evidence supports the effectiveness of the drug from in vitro experiments, and in vivo studies of aging mice, indicating is usefulness in preventing/treating one of the most pervasive forms of permanent hearing loss.